A one-year prospective, randomised, placebo-controlled, double-blind, phase II/III safety trial of combination therapy with IFN beta-1a (Avonex®) and mycophenolate mofetil (Cellcept®) in early multiple sclerosis

被引：0
|
作者：
Remington, G. [1 ]
Treadaway, K. [1 ]
Frohman, T. [1 ]
Shah, A. [1 ]
Salter, A. [1 ]
Racke, M. [1 ]
Frohman, E. [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S244 / S244
页数：1
相关论文
共 50 条
  • [21] Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
    Confavreux, Christian
    O'Connor, Paul
    Comi, Giancarlo
    Freedman, Mark S.
    Miller, Aaron E.
    Olsson, Tomas P.
    Wolinsky, Jerry S.
    Bagulho, Teresa
    Delhay, Jean-Luc
    Dukovic, Deborah
    Truffinet, Philippe
    Kappos, Ludwig
    LANCET NEUROLOGY, 2014, 13 (03): : 247 - 256
  • [22] Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial
    Chen, Ruchong
    Wei, Liping
    Dai, Yuanrong
    Wang, Zaiyi
    Yang, Danrong
    Jin, Meiling
    Xiong, Cui
    Li, Ting
    Hu, Shuling
    Song, Jie
    Chan, Robert
    Kumar, Subramanya
    Abdelkarim, Azza
    Zhong, Nanshan
    ERJ OPEN RESEARCH, 2024, 10 (03)
  • [23] Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
    Lublin, Fred
    Miller, David H.
    Freedman, Mark S.
    Cree, Bruce A. C.
    Wolinsky, Jerry S.
    Weiner, Howard
    Lubetzki, Catherine
    Hartung, Hans-Peter
    Montalban, Xavier
    Uitdehaag, Bernard M. J.
    Merschhemke, Martin
    Li, Bingbing
    Putzki, Norman
    Liu, Fonda C.
    Haering, Dieter A.
    Kappos, Ludwig
    LANCET, 2016, 387 (10023): : 1075 - 1084
  • [24] Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
    Khanna, Puja P.
    Khanna, Dinesh
    Cutter, Gary
    Foster, Jeff
    Melnick, Joshua
    Jaafar, Sara
    Biggers, Stephanie
    Rahman, A. K. M. Fazlur
    Kuo, Hui-Chien
    Feese, Michelle
    Kivitz, Alan
    King, Charles
    Shergy, William
    Kent, Jeff
    Peloso, Paul M.
    Danila, Maria I.
    Saag, Kenneth G.
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (08) : 1523 - 1532
  • [25] Efficacy and Safety of Two Dosing Frequencies of Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, REFLEX trial
    Stubinski, B.
    Kappos, L.
    Freedman, M. S.
    Comi, G.
    De Stefano, N.
    Barkhof, F.
    Polman, C. H.
    Uitdehaag, B. M. J.
    Casset-Semanaz, F.
    Hennessy, B.
    Rocak, S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (04) : 535 - 536
  • [26] Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis
    Andersen, O
    Elovaara, I
    Färkkilä, M
    Hansen, HJ
    Mellgren, SI
    Myhr, KM
    Sandberg-Wollheim, M
    Sorensen, PS
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (05): : 706 - 710
  • [27] Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial
    Mantero, J. C.
    Kishore, N.
    Ziemek, J.
    Stifano, G.
    Zammitti, C.
    Khanna, D.
    Gordon, J. K.
    Spiera, R.
    Zhang, Y.
    Simms, R. W.
    Lafyatis, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : S146 - S149
  • [28] Oral cladribine added to interferon beta-1a for active multiple sclerosis: a 96-week, double-blind, placebo-controlled phase IIb study
    Montalban, X.
    Cohen, B. A.
    Jeffery, D. R.
    Leist, T. P.
    Moses, H.
    Musch, B.
    MULTIPLE SCLEROSIS, 2007, 13 : S245 - S246
  • [29] Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study
    Pantzaris, Marios C.
    Bakirtzis, Christos
    Grigoriadis, Nikolaos
    Hadjigeorgiou, Georgios
    Dardiotis, Efthimos
    Loucaides, George
    Ntzani, Evangelia
    Markozannes, Georgios
    Omorfos, Savvas
    Valsasina, Paola
    Messina, Roberta
    Preziosa, Paolo
    Rocca, Maria A.
    Patrikios, Ioannis
    BMJ NEUROLOGY OPEN, 2022, 4 (02)
  • [30] Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
    Wynn, Daniel
    Kaufman, Michael
    Montalban, Xavier
    Vollmer, Timothy
    Simon, Jack
    Elkins, Jacob
    O'Neill, Gilmore
    Neyer, Lauri
    Sheridan, James
    Wang, Chungchi
    Fong, Alice
    Rose, John W.
    LANCET NEUROLOGY, 2010, 9 (04): : 381 - 390
12345